Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 04/10/24
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceGlobeNewsWire • 04/04/24
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesGlobeNewsWire • 03/18/24
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingGlobeNewsWire • 02/22/24
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksGlobeNewsWire • 01/22/24
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023GlobeNewsWire • 12/08/23
Pharvaris shares surge as treatment for severe swelling meets clinical trial goalMarket Watch • 12/06/23
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded WarrantsGlobeNewsWire • 12/06/23
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE AttacksGlobeNewsWire • 12/06/23
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations OfficerGlobeNewsWire • 11/15/23
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific MeetingGlobeNewsWire • 11/09/23
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/02/23